Beta-blocker to LOwer CArdiovascular Dialysis Events (BLOCADE) Feasibility Study

Principal Investigator: Dr Matthew Roberts
Clinical Research Associate: Liza Vergara (AKTN)
Trial Number: AKTN 08.01

Population: Dialysate patients aged over 50 years or under 18 years with a history of diabetes, MI, peripheral arterial disease or stroke

Final recruitment number: 72 (target of 150)
Intervention: Carvedilol (6.25-25mg) versus placebo, daily for 12 months
Primary outcome: Safety and tolerability of intervention as well as feasibility of recruitment

Results: The BLOCADE trial demonstrated the need for a very large pool of patients from which to recruit with greater international collaboration required. Results of the study have been published in the American Journal of Kidney Disease, and Nephrology.